Press Releases Immunocore Holdings plc

Equities

IMCR

US45258D1054

Market Closed - Nasdaq Other stock markets 01:30:00 03/05/2024 am IST			5-day change	1st Jan Change
59.46 ^USD	+0.69%		+2.52%	-12.97%

29/04	Leerink Partners Starts Immunocore Holdings With Outperform Rating, $74 Price Target	MT
21/03	Immunocore Holdings Files Mixed-Securities Shelf Registration	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Avacta Group plc - Christina Coughlin, MD, PhD, appointed Chief Executive Officer of Avacta Group	01/05	AQ
Immunocore announces upcoming presentation and posters at ASCO 2024	24/04	GL
Immunocore to present at upcoming investor conferences	05/04	GL
Immunocore presented two posters at CROI 2024	06/03	GL
Immunocore to present at upcoming investor conferences	01/03	GL
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update	28/02	GL
Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial	22/02	GL
Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024	21/02	GL
Immunocore Prices Upsized Convertible Senior Notes Offering	31/01	GL
Immunocore Prices Upsized Convertible Senior Notes Offering	31/01	AQ
Immunocore Announces Proposed Convertible Senior Notes Offering	30/01	GL
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation	05/01	GL
Immunocore to present at the 42nd Annual J.P. Morgan Healthcare Conference	03/01	GL
Immunocore to present at the 42nd Annual J.P. Morgan Healthcare Conference	03/01	AQ
Immunocore : Regulation FD Disclosure - Form 8-K	02/01	PU
Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update	07/11	GL
Immunocore announces upcoming poster presentations at SITC Annual Meeting 2023 and SMR Congress 2023	02/11	GL
Immunocore to present at upcoming investor conferences	31/23/31	GL
Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial	21/23/21	AQ
Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial	21/23/21	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Immunocore Holdings plc

Equities

IMCR

US45258D1054

Press Releases

Filters